Welcome to our dedicated page for Propanc Bio SEC filings (Ticker: PPCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech 10-K packed with clinical data can feel like deciphering lab notes. Propanc Biopharma’s disclosures dive deep into enzyme science, trial milestones, and consecutive capital raises—details that are critical yet easy to miss. If you have ever wondered, “How do I track Propanc Biopharma insider trading Form 4 transactions or find the next 8-K material event?”, you are not alone.
Stock Titan’s AI turns those dense PDFs into plain-English insights. We stream every Propanc Biopharma quarterly earnings report 10-Q filing, alert you to Propanc Biopharma Form 4 insider transactions in real-time, and surface red-flag language about going-concern risk within seconds. Our platform answers the exact questions investors type into search: “Propanc Biopharma SEC filings explained simply”, “understanding Propanc Biopharma SEC documents with AI”, or “Propanc Biopharma executive stock transactions Form 4”.
Here’s what you can uncover instantly:
- R&D spending on lead therapy PRP inside the annual report 10-K simplified
- Fresh funding rounds or licensing deals flagged in 8-K material events explained
- Upcoming trial timelines hidden in Propanc Biopharma earnings report filing analysis
- Board pay packages within the proxy statement executive compensation
No more scanning hundreds of pages—our expert analysis and AI-powered summaries connect each line item to its impact on future oncology milestones. Whether you need Propanc Biopharma insider trading Form 4 transactions or a quick brief before the next financing, every filing is here, updated the moment EDGAR posts it. Make informed decisions faster with complete, contextual coverage.
Propanc Biopharma (PPCB) filed its quarterly report for the three months ended September 30, 2025. The company reported no revenue and a net loss of $4,837,738, compared with a $354,310 loss a year ago. Operating expenses rose to $4,673,564 (from $290,790), driven mainly by administration expenses of $4,598,574, which included non‑cash items such as amortization of prepaid stock-based expenses.
Cash increased to $602,737 from $12,088, helped by financing inflows. The company completed an equity raise on August 18, 2025, selling 1,000,000 shares for $4,000,000 in gross proceeds and receiving approximately $3.3 million net. Total assets were $17,975,681, led by significant prepaid expenses, while total liabilities declined to $3,614,514 as convertible notes and related derivative balances decreased. The filing notes substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 12,806,748 at September 30, 2025, and 13,364,244 as of November 13, 2025.
Propanc Biopharma (PPCB) closed a private placement with Hexstone Capital, receiving $1,000,099 in cash for 100 shares of Series C Preferred Stock and issuing a warrant to purchase up to 9,900 additional Series C Preferred shares at an exercise price of $10,000 per warrant share. The securities were issued under Section 4(a)(2) and Rule 506 of Regulation D.
The company also created and authorized up to 9,900 shares of Series C Preferred through a Certificate of Designation. Each preferred share has a stated amount of $10,000 and is convertible into common stock at the lesser of a fixed $5.00 per share or 85% of the lowest trading price during a defined period with a five trading day minimum and a volume condition. This brings in immediate cash and sets terms for potential future conversions and warrant exercises.
Propanc Biopharma (PPCB) entered a Securities Purchase Agreement for a private placement of a new Series C Preferred Stock class. The deal with Hexstone Capital provides for the issuance of 100 Series C Preferred shares at closing and a Warrant to purchase up to an additional 9,900 Series C Preferred shares. Each Series C Preferred share is convertible into common stock at the lesser of a fixed $5.00 per-share conversion price or 85% of the lowest trading price during a defined period tied to a holder’s conversion notice, with a five trading day minimum. The closing is conditioned on filing the Certificate of Designation for the Series C Preferred with Delaware.
Propanc Biopharma, Inc. (PPCB) reported financials highlighting severe liquidity and solvency pressures. The company recorded an accumulated deficit of $125,621,520 and net cash used in operations of $405,168. It had no cash equivalents at June 30, 2025. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months.
The filing discloses a 1:60,000 Reverse Stock Split effective January 29, 2025, numerous loans and convertible notes with defaults or past due maturities, and debt-exchange transactions that settled loans for common stock (e.g., 30,000 shares issued to settle $86,248 of loans). The company lists extensive granted patents and patent validations for its proenzyme/proenzyme compositions across many jurisdictions. It completed a registered offering that produced $3.34 million net proceeds.
FAQ
What is the current stock price of Propanc Bio (PPCB)?
What is the market cap of Propanc Bio (PPCB)?
